Table 6A.
Model-adjusted means* (SEM) and corresponding P-values for health-related outcomes and ADG from Day 0 to closeout by treatment group for steers with a WS = 1.
| Parameter | Saline1 | FTS1 | TIL1 | TIL + FTS1 | P-value FTSα | P-value TILβ | P-value TIL + FTSδ |
|---|---|---|---|---|---|---|---|
| BRD case-fatality (%) | 3.5 (1.4) | 4.2 (1.1) | 4.0 (1.1) | 2.6 (0.9) | 0.73 | 0.64 | 0.35 |
| Removals (%) | 2.4 (1.2)a | 5.2 (1.2)a, b | 3.7 (1.0)a | 1.2 (0.6)a, c | 0.66 | 0.19 | 0.02** |
| DNF (%)2 | 5.7 (1.8)a | 8.7 (1.6)a, b | 7.4 (1.5) a | 3.8 (1.0)a, c | 0.61 | 0.25 | 0.03 |
| Adjusted-ADG (lbs/day)3 | 3.3 (0.04) | 3.3 (0.03) | 3.3 (0.03) | 3.3 (0.03) | 0.39 | 0.36 | 0.51 |
Mixed models with a random effect to account for lack of independence among treatment groups within pens, and pens within 2 different sites.
Different superscripts denote significant differences (P ≤ 0.05) between treatment groups; Pairwise comparisons were only evaluated if the interaction effect (TIL + FTS) was observed to be statistically significant (P ≤ 0.05). All pairwise comparisons were adjusted for multiple comparisons (Tukey method).
Saline, negative control; FTS, Flunixin transdermal solution; TIL, tildipirosin; and TIL + FTS, concurrent administration of TIL and FTS.
DNF, did not finish; a combination of both calves that died or were removed due to BRD from Day 0-closeout of this study.
Adjusted-ADG: adjusted Average Daily Gain based on a 63% carcass yield.
P-values reflect the overall effect of FTS, TIL, and their interaction, respectively. P-values for each main effect reflect a model-adjusted average between treatments incorporating the product compared to those that do not. For example, the P-value for the FTS main effect reflects the comparison between treatments that implement FTS (i.e., FTS and TIL+FTS) vs. those that do not (i.e., Saline + TIL). Only when the P-value for the interaction is significant (P ≤ 0.05) are direct comparison made between the four treatment groups.
P-value for main effect of Flunixin transdermal solution.
P-value for main effect of tildipirosin.
P-value for interaction of tildipirosin and Flunixin transdermal solution.